Trial Profile
A study investigaing risk factors associated with Ranibizumab treatment leading to the development and progression of retinal pigment epithelial (RPE) atrophy in Japanese patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- 11 May 2016 New trial record